Compare Cytokinetics Inc (CYTK) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Oatly Group AB - ADR — how do they compare? Cytokinetics Inc trades at $77.57 (market cap $10.63B), while Oatly Group AB - ADR trades at $13.11 (market cap $415.98M). The key difference: Cytokinetics Inc is far larger — about 25.6× Oatly Group AB - ADR's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| CYTK | OTLY | |
|---|---|---|
Market Cap | $10.63B | $415.98M |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $18.54 |
52-Week Low | $34.31 | $8.03 |
Enterprise Value | $10.74B | $920.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
OTLY trades at $13.12, down 4.37% today, but maintains a bullish technical outlook with strong moving average and oscillator signals. The company reported Q2 2026 revenue growth and raised full-year guidance, showing progress toward profitability with improving gross margins. However, negative net income and cash flow challenges persist, with the stock trading at a low P/S ratio of 0.44 but elevated P/B of 79.9.
The investment case hinges on OTLY's operational turnaround and revenue acceleration, but significant risks remain from cash burn and high debt levels. Analyst sentiment is mixed with 44% buy ratings, while technical indicators suggest near-term support at $13. The path to sustainable profitability remains the key catalyst for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
